Europe could be hit by serious medicines shortages if too many markets enforce onerous stockpiling measures at the same time, the Swedish pharmaceutical industry group has claimed.
Introducing obligations for drug manufacturers to increase stock levels and cover the expense involved could increase costs for companies and force them to withdraw their products from the market, according to Bengt Mattson, head of pharmaceutical supply at the Swedish pharmaceutical industry association, Lif.
The comments follow a recent government inquiry into security of supply in times of crisis and war, and as Sweden’s...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
